Buy, Sell, Or Hold MRNA Stock?

By Forbes | Nov 7, 2024 at 09:43 AM EST

Moderna's stock price dropped by 48% this year but is expected to rebound after strong Q3 results. The company beat revenue estimates due to high Covid-19 vaccine sales. With a promising RSV vaccine and cost-cutting measures, Moderna looks undervalued at $50.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.